Casacchia M, Rossi A
Clinica Psichiatrica dell'Università de L'Aquila, Italy.
Pharmacopsychiatry. 1989 Jul;22(4):152-5. doi: 10.1055/s-2007-1014598.
Moclobemide, a new reversible anti-MAO drug, was compared to imipramine in forty patients with major depression or dysthymic disorder. After a one-week wash-out period, patients were randomly allocated to the two treatment groups, receiving imipramine 25 mg tablets or Moclobemide 50 mg capsules for 28 days. Efficacy and tolerability were investigated by means of HRSD, CGI and VAS at baseline and thereafter at days 3, 7, 14 and 28. All patients completed the study, mean daily doses were 112.5 mg imipramine and 215 mg Moclobemide at day 28. Both treatments had similar antidepressant efficacy and a very good tolerability profile. Moclobemide was superior to imipramine in mean time to onset of effect (7.3 days versus 11.6 days: p less than 0.05) and in mean time to peak effect (13.5 days versus 18.5 days: 0.10 greater than p greater than 0.05. It is concluded that Moclobemide is a safe and effective anti-MAO drug, with an increasing rapid onset of therapeutic activity.
吗氯贝胺是一种新型可逆性单胺氧化酶抑制剂，在40例重度抑郁症或心境恶劣障碍患者中，将其与丙咪嗪进行了比较。经过一周的洗脱期后，患者被随机分配到两个治疗组，分别服用25毫克丙咪嗪片或50毫克吗氯贝胺胶囊，持续28天。在基线以及之后的第3、7、14和28天，通过汉密尔顿抑郁量表（HRSD）、临床总体印象量表（CGI）和视觉模拟量表（VAS）对疗效和耐受性进行了研究。所有患者均完成了研究，在第28天，丙咪嗪的平均日剂量为112.5毫克，吗氯贝胺的平均日剂量为215毫克。两种治疗方法具有相似的抗抑郁疗效和非常好的耐受性。吗氯贝胺在起效平均时间（7.3天对11.6天：p<0.05）和达到峰值效应的平均时间（13.5天对18.5天：0.10>p>0.05）方面优于丙咪嗪。得出的结论是，吗氯贝胺是一种安全有效的单胺氧化酶抑制剂，治疗活性起效较快。
